PreludeDx Validates AidaBreast™ for Breast Cancer Prognosis
Today, Prelude Corporation, commonly known as PreludeDx, a frontrunner in precision diagnostics for early-stage breast cancer, proudly shares significant findings about AidaBreast™, an innovative multi-omic test. This recent validation marks a substantial step forward for women diagnosed with early-stage invasive breast cancer, particularly regarding how healthcare providers assess locoregional recurrence risk and radiation therapy benefits.
AidaBreast™: A Novel Approach
AidaBreast™ employs groundbreaking technology to offer a multi-dimensional view of tumor biology. Unlike traditional methods, which largely rely on single biomarkers, AidaBreast™ combines analysis of RNA and protein expressions along with spatial biology, offering a thorough insight into a patient's cancer behavior.
Results from Clinical Validation
The validation study involved over 400 women with early-stage HR+ / HER2- invasive breast cancer. The results were compelling: AidaBreast™ successfully stratified women into Low Risk and Elevated Risk categories based on their tumor's biological makeup. Within the Elevated Risk group, it remarkably identified candidates likely to reap significant advantages from radiation therapy (RT) versus those who would not see considerable benefits despite higher risks of recurrence.
Freedom from Unnecessary Treatment
For women classified in the Low Risk group, the study indicated exceptionally low 10-year recurrence rates, regardless of radiation therapy exposure. Dr. Bruce Mann, one of the lead researchers, emphasizes that this validation demonstrates that AidaBreast™ can guide clinical decisions about whether radiation therapy is necessary.
Advancements in Treatment Decisions
The potential to make informed treatment choices resonates deeply with both patients and healthcare providers. Dan Forche, the President and CEO of PreludeDx, conveyed the significant breakthrough of having a tool that allows women diagnosed with Stage I and IIa breast cancer to participate actively in their treatment options.
Future Perspectives on AidaBreast™
The implications of AidaBreast™ stretch beyond just radiation therapy; upcoming evaluations promise to enhance understanding related to endocrine therapy and chemotherapy treatments as well. This comprehensive decision-support system aims to empower women with greater insights into their options moving towards a more personalized cancer care model.
Connecting Previous Innovations
AidaBreast™ is built upon PreludeDx's strong foundation established by their previous test, DCISionRT®. This earlier test transformed decision-making processes related to radiation therapy in patients diagnosed with ductal carcinoma in situ, which serves as a testament to the company's commitment to providing cutting-edge tools tailored for breast cancer treatment.
About PreludeDx
Founded in 2009, PreludeDx has emerged as a leader in personalized breast cancer diagnostics. They are dedicated to advancing technologies that can meaningfully impact treatment decisions for patients worldwide. Their mission centers around improving patient outcomes while simultaneously aiming to reduce healthcare costs. For additional resources and information about PreludeDx and its contributions to breast cancer diagnostics, visit their official website.
Frequently Asked Questions
What is AidaBreast™?
AidaBreast™ is a multi-omic test designed to predict the risk of locoregional recurrence in early-stage invasive breast cancer and evaluate the potential benefits of radiation therapy.
How does AidaBreast™ assist in treatment decisions?
The test stratifies patients into risk categories and identifies who will benefit most from radiation therapy, helping healthcare providers make informed treatment choices.
What are the next steps for AidaBreast™?
AidaBreast™ will continue to evolve, with future plans to assess benefits related to endocrine therapy and chemotherapy, broadening its applicability.
How does AidaBreast™ compare to previous tests?
Unlike earlier tests that focused primarily on metastatic risks, AidaBreast™ amalgamates information from RNA and functional proteins to provide comprehensive insights into tumor biology.
Who benefits from the findings of this study?
The findings specifically provide invaluable insights for women diagnosed with early-stage invasive breast cancer and their healthcare providers in making treatment decisions.
